Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease
Launched by TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN · Jan 15, 2014
Trial Information
Current as of July 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Approximately 50 pediatric orthopaedic surgeons from pediatric centers in the US and other countries have agreed to participate in this database as members of the International Perthes Study Group (IPSG). TSRH will be the lead center. Sites who agree to participate will seek IRB approval from their own institutions. Data will be collected prospectively and entered into REDCap (Research Electronic Data Capture), a browser-based research database.
1-6 Cohort: For the 1-6 age patient group, patients involved in any treatment will be asked to participate in the study.
6-8 Cohort: For the 6-8 ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with Legg-Calvé-Perthes disease
- • Between age 1-18
- • Patients with possible secondary femoral osteonecrosis if over the age of 11 due to trauma or corticosteroid therapy are also eligible.
- Exclusion Criteria:
- • Patients with previous surgical treatment on the affected hip
About Texas Scottish Rite Hospital For Children
Texas Scottish Rite Hospital for Children (TSRHC) is a premier pediatric orthopedic hospital renowned for its commitment to providing exceptional care and innovative treatment for children with musculoskeletal conditions. As a leading clinical trial sponsor, TSRHC is dedicated to advancing pediatric healthcare through rigorous research, fostering an environment of collaboration among healthcare professionals, researchers, and families. The hospital prioritizes the safety and well-being of its patients while driving forward the development of cutting-edge therapies and interventions that enhance the quality of life for children facing orthopedic challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Philadelphia, Pennsylvania, United States
Vancouver, British Columbia, Canada
Cincinnati, Ohio, United States
Houston, Texas, United States
Hartford, Connecticut, United States
Washington, District Of Columbia, United States
Portland, Oregon, United States
Aurora, Colorado, United States
Columbus, Ohio, United States
Seattle, Washington, United States
San Juan, , Puerto Rico
Orlando, Florida, United States
Bronx, New York, United States
Oklahoma City, Oklahoma, United States
Chicago, Illinois, United States
Los Angeles, California, United States
Dallas, Texas, United States
Baltimore, Maryland, United States
Charlotte, North Carolina, United States
Uppsala, , Sweden
Madrid, , Spain
Saint Paul, Minnesota, United States
Seoul, , Korea, Republic Of
Birmingham, Alabama, United States
Los Angeles, California, United States
San Diego, California, United States
Wilmington, Delaware, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Boston, Massachusetts, United States
New York, New York, United States
New York, New York, United States
Germantown, Tennessee, United States
Salt Lake City, Utah, United States
Adelaide, South Australia, Australia
São Paulo, , Brazil
Calgary, Alberta, Canada
Tianjin, , China
Hamburg, , Germany
Lübeck, , Germany
Lübeck, , Germany
Udupi, Karnataka, India
Oslo, , Norway
łódź, , Poland
Liverpool, , United Kingdom
Southampton, , United Kingdom
Lausanne, , Switzerland
Dublin, , Ireland
San Francisco, California, United States
Patients applied
Trial Officials
Harry KW Kim, MD, MS
Study Chair
Texas Scottish Rite Hospital for Children
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials